Report on the NIH Workshop on Pharmacologic Treatment of Obesity
American Journal of Clinical NutritionPublished 1 August 1994
RL Atkinson, VS Hubbard
Citations48
SJR quartileQ1
SJR score2.11
SNIP1.75
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is concluded that pharmacologic agents may be effective in reducing body weight over an extended period of time and industry, professional societies, and governmental agencies should work together to explore the potential for drugs for obesity.
Abstract
A National Institutes of Health workshop on pharmacologic treatment of obesity concluded that pharmacologic agents may be effective in reducing body weight over an extended period of time. Drugs should be used as only one component of a comprehensive weight-reduction program, and additional research is needed on the long-term efficacy and safety of drugs for obesity, and especially for combinations of drugs. Improvement in comorbidities and risk factors of obesity should be used along with weight reduction as an outcome measure in clinical trials. Industry, professional societies, and governmental agencies should work together to explore the potential for drugs for obesity and to reassess the regulatory and administrative controls on the use of currently available drugs for obesity and on the approval process for future drugs.
Keywords
Medicine
Endocrine ReviewsNeuropeptide Regulation of Appetite and Weight*
593 Citations1987John E. Morley
The role of peptides as modulators of feeding behavior and weight regulation is focused on and peptides synthesized and released in the central nervous system and act as neurotransmitters are studied.
American Journal of Clinical NutritionEconomic costs of obesity
314 Citations1992Graham A. Colditz
The costs of treatment for severe obesity must be weighed against the improved health status and quality of life, and addition of costs due to musculoskeletal disorders could raise this estimate to 7.8%.
The LancetINTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
310 Citations1989B Guy-Grand, Gaetano Crepaldi +4 more
In a randomised, placebo-controlled, double-blind study, 822 obese patients of both sexes were given either dexfenfluramine, 15 mg twice daily (404), or placebo in addition to a calorie-restricted diet for 1 year.
American Journal of Clinical NutritionPrevalence of overweight and weight gain in the United States
292 Citations1992RJ Kuczmarski
Data from the Second National Health and Nutrition Examination Survey indicated that in the period 1976-1980 approximately 34 million US adults were overweight, with more women than men affected, and women had a greater mean weight gain.
DrugsAppetite Suppressants
183 Citations1992Trevor Silverstone
Of the compounds currently indicated for use in obesity, dexfenfluramine appears to have the most suitable pharmacological profile, although it should not be given to patients with a history of depression.
Clinical Pharmacology & TherapeuticsLong-term weight control study I (weeks 0 to 34)
173 Citations1992Michael Weintraub, P. R. Sundaresan +5 more
Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks.
Annals of Internal MedicineMethods for Voluntary Weight Loss and Control
167 Citations1992NIH Technology Assessment Conference Panel
Survey data confirm that many Americans who are not overweight, particularly young women, are trying to lose weight, which may have adverse physical and psychological consequences.
Clinical Pharmacology & TherapeuticsLong-term weight control study: Conclusions
162 Citations1992Michael Weintraub
Obesity in America
136 Citations2018George A. Bray
PubMedEphedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis.
91 Citations1993Abdul G. Dulloo
Future research aimed at clarifying the types and subtypes of these negative modulators of sympathomimetic-induced thermogenesis and their targeting by more selective antagonists would no doubt be pivotal in providing the safe drug combination with the necessary thermogenic properties to assist the management of obesity.
Clinical Pharmacology & TherapeuticsLong-term Weight Control Study VI
86 Citations1992Michael Weintraub, P. R. Sundaresan +1 more
Clinical Pharmacology & TherapeuticsLong-term weight control study II (weeks 34 to 104)
74 Citations1992Michael Weintraub, P. R. Sundaresan +6 more
Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years.
Annals of Internal MedicineProposed Standards for Judging the Success of the Treatment of Obesity
63 Citations1993Richard L. Atkinson
The standards for success of treatment of obesity listed here are broadly based, arbitrary criteria derived from the current technology for obesity treatment, which federal health care and regulatory agencies, insurance companies, and other organizations may find useful, but it should be remembered that these definitions are not meant to be rigid.
Clinical Pharmacology & TherapeuticsLong-term weight control study III (weeks 104 to 156)
61 Citations1992Michael Weintraub, P. R. Sundaresan +3 more
Between weeks 104 and 156 the authors attempted to optimize response by adjusting the doses of fenfluramine and phentermine using an algorithm that aimed to achieve 120% of ideal body weight (IBW) while minimizing adverse effects.
International Journal of Eating DisordersFenfluramine suppresses snack intake among carbohydrate cravers but not among noncarbohydrate cravers
59 Citations1987Judith J. Wurtman, Richard J. Wurtman +3 more
D-fenfluramine significantly reduced the intakes of calories and carbohydrates from snacks among the carbohydrate cravers over a three month treatment period and had no effect on mealtime carbohydrate nor protein intake by noncarbohydrate cravers.
PubMedRelative weight classifications in the assessment of underweight and overweight in the United States.
57 Citations1992Rosely Sichieri, James E. Everhart +1 more
Five recent relative weight classifications based on body mass index were compared for their estimates of prevalence of underweight and overweight in the adult population of the United States and for their ability to predict subsequent morbidity and mortality.
PubMedSafety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture.
57 Citations1993S Toubro, Arne Astrup +2 more
It is concluded that the ephedrine/caffeine combination is effective in improving and maintaining weight loss, further it has lean body mass saving properties and the mentioned compound showedLean body mass conserving properties.
Clinical Pharmacology & TherapeuticsLong-term weight control study V (weeks 190 to 210)
55 Citations1992Michael Weintraub, P. R. Sundaresan +4 more
The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants.
Clinical Pharmacology & TherapeuticsLong-term weight control study IV (weeks 156 to 190)
54 Citations1992Michael Weintraub, P. R. Sundaresan +5 more
Fenfluramine plus phentermine provided better appetite control and only slightly more bother than placebo added to behavior modification, caloric restriction, and exercise and initial receipt of medication did not have negative learning effects.
Annals of Internal MedicineBarriers to the Treatment of Obesity
52 Citations1991George A. Bray
There is clear and convincing evidence that modern appetite-suppressant drugs are effective and safe, however, there are several barriers to the proper use of these drugs and other treatments.
Diabetic MedicineThe Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes
45 Citations1992K. Willey, Lynda Molyneaux +2 more
Dexfenfluramine is a valuable adjunct to the treatment of the overweight patient with Type 2 diabetes and should be added to existing treatment regimens of metformin with or without a sulphonylurea.
Clinical Pharmacology & TherapeuticsLong-term weight control study VII (weeks 0 to 210)
41 Citations1992Michael Weintraub, P. R. Sundaresan +1 more
Overall, participants in the long‐term weight control study had beneficial changes in their lipid profiles, thus decreasing their risk of coronary heart disease, and greater decreases in serum total cholesterol, LDL‐C, and triglyceride levels were observed in participants with high compared with low baseline lipid levels.
American Journal of Clinical NutritionClinical studies with the β-adrenoceptor agonist BRL 26830A
36 Citations1992A. A. Connacher, WM Bennet +1 more
PubMedThe acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study.
26 Citations1993Luca Scalfi, E D'Arrigo +3 more
It is shown that in obese subjects dFE increases energy expenditure in the post-absorptive state, as well as after the ingestion of food.
PubMedBody weight evolution during dexfenfluramine treatment after initial weight control.
21 Citations1992Nick Finer
While very low calorie diets (VLCD) can lead to rapid weight loss, even in patients who have often failed with conventional diets, maintaining this loss remains a clinical challenge, drugs to maintain and improve upon initial VLCD success would be of clinical benefit.
American Journal of Clinical NutritionAppraisal of the clinical value of serotoninergic drugs
7 Citations1992J. F. Munro, CRANFORD L. SCOTT +1 more
Serotonin agonists are of clinical value if there is a short-term need for weight reduction or if long-term pharmacotherapy can be justified, and if the same agent also improves diabetic control, blood pressure, or depression then a longer term usage is more readily justified.